X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4841) 4841
Book Review (498) 498
Publication (312) 312
Magazine Article (11) 11
Conference Proceeding (10) 10
Book Chapter (6) 6
Newsletter (5) 5
Dissertation (4) 4
Book / eBook (2) 2
Newspaper Article (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (4379) 4379
humans (3226) 3226
benzoates - therapeutic use (2741) 2741
male (2181) 2181
animals (1761) 1761
female (1737) 1737
benzoates - pharmacology (1269) 1269
pharmacology & pharmacy (972) 972
middle aged (935) 935
adult (909) 909
benzimidazoles - therapeutic use (842) 842
rats (756) 756
aged (672) 672
benzoates - administration & dosage (632) 632
mice (626) 626
telmisartan (503) 503
treatment outcome (501) 501
hypertension - drug therapy (467) 467
benzoates - adverse effects (454) 454
angiotensin ii type 1 receptor blockers - therapeutic use (431) 431
triazoles - therapeutic use (393) 393
abridged index medicus (383) 383
adolescent (380) 380
hematology (375) 375
hypertension (353) 353
iron chelating agents - therapeutic use (350) 350
benzoates - chemistry (347) 347
benzimidazoles - pharmacology (344) 344
blood pressure - drug effects (328) 328
child (317) 317
dose-response relationship, drug (316) 316
drug therapy, combination (313) 313
pyrazoles - therapeutic use (311) 311
time factors (308) 308
hydrazines - therapeutic use (305) 305
analysis (301) 301
angiotensin-converting enzyme inhibitors - therapeutic use (299) 299
antihypertensive agents - therapeutic use (290) 290
benzoic acid (249) 249
oncology (241) 241
disease models, animal (238) 238
rats, sprague-dawley (233) 233
deferasirox (226) 226
peripheral vascular disease (226) 226
administration, oral (221) 221
biochemistry & molecular biology (214) 214
clinical trials as topic (211) 211
child, preschool (210) 210
research (209) 209
iron overload - drug therapy (208) 208
double-blind method (207) 207
expression (205) 205
oxidative stress (205) 205
benzoates (204) 204
benzimidazoles - administration & dosage (203) 203
efficacy (201) 201
care and treatment (200) 200
neurosciences (198) 198
benzoates - pharmacokinetics (194) 194
health aspects (194) 194
medicine, general & internal (192) 192
young adult (189) 189
drug combinations (186) 186
drug therapy (186) 186
angiotensin ii type 1 receptor blockers - pharmacology (180) 180
rats, wistar (180) 180
chemistry, medicinal (177) 177
sodium benzoate (177) 177
therapy (176) 176
medicine & public health (175) 175
risk factors (168) 168
receptors, thrombopoietin - agonists (167) 167
in-vitro (165) 165
inflammation (162) 162
hypertension - physiopathology (157) 157
toxicology (157) 157
blood-pressure (156) 156
prospective studies (156) 156
purpura, thrombocytopenic, idiopathic - drug therapy (156) 156
article (154) 154
mice, inbred c57bl (152) 152
safety (147) 147
disease (144) 144
eltrombopag (144) 144
in vitro techniques (144) 144
double-blind (142) 142
rodents (141) 141
apoptosis (140) 140
medicine, research & experimental (140) 140
aged, 80 and over (139) 139
internal medicine (139) 139
pediatrics (139) 139
angiotensin (138) 138
benzimidazoles - adverse effects (137) 137
cells, cultured (136) 136
benzoates - metabolism (135) 135
cardiac & cardiovascular systems (135) 135
randomized controlled trials as topic (135) 135
management (134) 134
cancer (133) 133
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4238) 4238
German (180) 180
French (147) 147
Russian (74) 74
Japanese (60) 60
Italian (51) 51
Spanish (38) 38
Chinese (17) 17
Polish (13) 13
Danish (9) 9
Czech (7) 7
Hungarian (6) 6
Portuguese (5) 5
Dutch (4) 4
Norwegian (4) 4
Romanian (4) 4
Slovak (2) 2
Turkish (2) 2
Bulgarian (1) 1
Lithuanian (1) 1
Serbian (1) 1
Swedish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 09/2008, Volume 359, Issue 12, pp. 1238 - 1251
In this large clinical trial, aspirin plus extended-release dipyridamole was found to have an efficacy similar to that of clopidogrel in the prevention of... 
ISSUES | MEDICINE, GENERAL & INTERNAL | PLACEBO | DESIGN | TICLOPIDINE | WARFARIN | TRANSIENT ISCHEMIC ATTACK | DOUBLE-BLIND | PREVENTION | REGIMENS | NON-INFERIORITY TRIALS | Myocardial Infarction - epidemiology | Benzoates - therapeutic use | Ticlopidine - therapeutic use | Humans | Middle Aged | Male | Risk | Secondary Prevention | Aspirin - administration & dosage | Vascular Diseases - mortality | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Dipyridamole - adverse effects | Female | Stroke - epidemiology | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Dipyridamole - therapeutic use | Benzimidazoles - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Brain Ischemia - epidemiology | Stroke - prevention & control | Double-Blind Method | Kaplan-Meier Estimate | Proportional Hazards Models | Brain Ischemia - prevention & control | Factor Analysis, Statistical | Stroke - drug therapy | Ticlopidine - analogs & derivatives | Aged | Hemorrhage - chemically induced | Delayed-Action Preparations | Stroke (Disease) | Aspirin | Usage | Care and treatment | Dipyridamole | Clopidogrel | Health aspects | Stroke | Index Medicus | Abridged Index Medicus | Recurrence | Brain Ischemia | Benzimidazoles | Follow-Up Studies | Neurons and Cognition | Cognition | Hemorrhage | Drug Delivery Systems | Life Sciences | Angiotensin II Type 1 Receptor Blockers | Angiotensin-Converting Enzyme Inhibitors | Vascular Diseases | Mental Status Schedule | Retrospective Studies | Severity of Illness Index | Disability Evaluation | Benzoates | Drug Administration Schedule | International Cooperation | Ticlopidine | Myocardial Infarction | Platelet Aggregation Inhibitors | Santé publique et épidémiologie | Original | Dipyridamole/adverse effects/therapeutic use | Angiotensin-Converting Enzyme Inhibitors/therapeutic use | Recurrence/prevention & control | Benzoates/therapeutic use | Brain Ischemia/epidemiology/prevention & control | MEDICIN OCH HÄLSOVETENSKAP | Platelet Aggregation Inhibitors/administration & dosage/adverse | Combination | MEDICAL AND HEALTH SCIENCES | Aspirin/administration & dosage/adverse effects | Myocardial Infarction/epidemiology | Factor Analysis | Benzimidazoles/therapeutic use | Drug Therapy | Ticlopidine/adverse effects/analogs & derivatives/therapeutic use | effects/therapeutic use | Vascular Diseases/mortality | Hemorrhage/chemically induced | Stroke/drug therapy/epidemiology/prevention & control | Statistical | Kaplan-Meiers Estimate
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2017, Volume 376, Issue 16, pp. 1540 - 1550
Journal Article
PLoS ONE, ISSN 1932-6203, 06/2018, Volume 13, Issue 6, pp. e0198184 - e0198184
Background Many patients with immune thrombocytopenia (ITP) may require special attention and long-term treatment. Little is known on the efficacy and... 
AUTOIMMUNE THROMBOCYTOPENIA | TREATMENT OPTIONS | ADULT PATIENTS | INTRAVENOUS GAMMA-GLOBULIN | MANAGEMENT | ANTI-D | MEDICAL THERAPY | SAFETY | PURPURA | ROMIPLOSTIM | MULTIDISCIPLINARY SCIENCES | Prednisolone - adverse effects | Azathioprine - therapeutic use | Pyrazoles - therapeutic use | Benzoates - therapeutic use | Recombinant Fusion Proteins - adverse effects | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Immunoglobulins, Intravenous - adverse effects | Child, Preschool | Dexamethasone - adverse effects | Male | Dapsone - therapeutic use | Purpura, Thrombocytopenic, Idiopathic - drug therapy | Receptors, Fc - therapeutic use | Splenectomy | Young Adult | Aged, 80 and over | Child | Rituximab - adverse effects | Purpura, Thrombocytopenic, Idiopathic - surgery | Combined Modality Therapy | Remission Induction | Cyclosporine - therapeutic use | Dexamethasone - therapeutic use | Immunoglobulins, Intravenous - therapeutic use | Rho(D) Immune Globulin - adverse effects | Cyclosporine - adverse effects | Adolescent | Rho(D) Immune Globulin - therapeutic use | Dapsone - adverse effects | Benzoates - adverse effects | Recombinant Fusion Proteins - therapeutic use | Thrombopoietin - therapeutic use | Purpura, Thrombocytopenic, Idiopathic - therapy | Rituximab - therapeutic use | Adult | Female | Prednisolone - therapeutic use | Retrospective Studies | Drug Therapy, Combination | Drug Resistance | Pyrazoles - adverse effects | Hydrazines - therapeutic use | Treatment Outcome | Thrombopoietin - adverse effects | Immunosuppressive Agents - adverse effects | Aged | Azathioprine - adverse effects | Hydrazines - adverse effects | Thrombocytopenic purpura | Clinical trials | Treatment outcome | Care and treatment | Analysis | Drugs | Thrombocytopenia | Therapy | Immunoglobulins | Dexamethasone | Intravenous administration | Medical treatment | Medical services | Patients | Immunosuppressive agents | Bleeding | Medicine | Remission | Clinical medicine | Azathioprine | Drug dosages | Prednisolone | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2014, Volume 371, Issue 24, pp. 2255 - 2266
Journal Article
Gastroenterology, ISSN 0016-5085, 2014, Volume 146, Issue 2, pp. 442 - 452.e1
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2008, Volume 358, Issue 15, pp. 1547 - 1559
This large trial compared the angiotensin-receptor blocker telmisartan, the angiotensin-converting–enzyme inhibitor ramipril, and combination therapy with both... 
MEDICINE, GENERAL & INTERNAL | DESIGN | LEFT-VENTRICULAR DYSFUNCTION | MYOCARDIAL-INFARCTION | CARDIOVASCULAR EVENTS | DOUBLE-BLIND | SYSTOLIC DYSFUNCTION | RANDOMIZED CLINICAL-TRIALS | CONGESTIVE-HEART-FAILURE | COMBINATION | CONVERTING-ENZYME-INHIBITORS | Benzoates - adverse effects | Angiotensin II Type 1 Receptor Blockers - adverse effects | Benzoates - therapeutic use | Follow-Up Studies | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Cardiovascular Diseases - drug therapy | Humans | Middle Aged | Male | Risk | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Blood Pressure - drug effects | Ramipril - therapeutic use | Benzimidazoles - adverse effects | Drug Therapy, Combination | Ramipril - adverse effects | Benzimidazoles - therapeutic use | Double-Blind Method | Diabetes Mellitus - drug therapy | Kaplan-Meier Estimate | Hospitalization | Creatinine - blood | Angioedema - chemically induced | Aged | Complications and side effects | Ramipril | Drug therapy, Combination | Diabetes | Cardiovascular diseases | Drug therapy | Comparative analysis | Risk factors | Telmisartan | Clinical trials | Vein & artery diseases | Cardiovascular disease | Pharmacology | Clinical outcomes | Index Medicus | Abridged Index Medicus | Blood Pressure | Benzimidazoles | Cardiovascular Diseases | MEDICIN OCH HÄLSOVETENSKAP | Angiotensin II Type 1 Receptor Blockers | epidemiology | Angiotensin-Converting Enzyme Inhibitors | Combination | MEDICAL AND HEALTH SCIENCES | Creatinine | chemically induced | Benzoates | drug therapy | Angioedema | drug effects | Diabetes Mellitus | blood | adverse effects | mortality | therapeutic use | Kaplan-Meiers Estimate
Journal Article